J Formos Med Assoc 1993 Jun;92(6):536-9
Department of Obstetrics and Gynecology, National Cheng Kung University Medical College, Tainan, Taiwan, R.O.C.
Int J Fertil Menopausal Stud 1994 May-Jun;39(3):150-5
Department of Obstetrics and Gynecology, Carmel Hospital, Haifa, Israel.
Purpose: Uterine leiomyomata alone are an infrequent cause of infertility. We presumed that--since the smaller the uterine size at the time of myomectomy, the greater the chances of subsequent conception--diminishing the preoperative tumor size in infertile patients with large leiomyomata prior to myomectomy should be beneficial.
Procedure: Decapeptyl (D-Trp6-LHRH) depot 3. Read More
Clin Exp Obstet Gynecol 2002 ;29(3):222-4
'Department of Obstetrics and Gynecology, Gaziantep University, School of Medicine, Gaziantep, Turkey.
In this prospective, randomized, double-blind study, we evaluated the effects of tibolone therapy in association with preoperative gonadotropin releasing hormone agonist (GnRHa) therapy on the reduction of myoma volume. Twenty patients with myoma uteri were divided into two groups. Group I was given monthly triptoreline (3. Read More
Cochrane Database Syst Rev 2000 (2):CD000547
Department of Obstetrics and Gynaecology, University of Auckland, 2nd Floor, National Women's Hospital, Claude Road, Epsom, Auckland, New Zealand.
Background: Uterine fibroids, smooth muscle tumours of the uterus, are found in at least 25 to 35% of women over the age of 35 years. Although some of these tumours are asymptomatic, up to 50% cause symptoms severe enough to warrant therapy and surgery is the standard treatment. Fibroid growth is stimulated by oestrogen and gonadotropin releasing hormone agonists (GnRHa) which induce a state of hypoestrogenism have been investigated as a potential treatment. Read More
Kaohsiung J Med Sci 2000 Feb;16(2):103-7
Kang-Ning Junior College of Nursing, Taipei, Taiwan.
Gonadotropin releasing hormone agonist (GnRH-agonist) therapy has been useful as an adjunct before myomectomy or hysterectomy for uterine myoma but the concealed risk is often overlooked. We report an extremely rare clinical presentation of a patient with multiple submucosal myomata during the treatment of long-acting gonadotropin-releasing hormone agonist (GnRH-agonist) in a 23-year-old, virgin woman. This patient exhibited heavy menstruation and severe anemia for half of a year. Read More